Report Sections

See All Reports

  • HP:0000083: Renal insufficiency
  • Pneumonia (359) Respiratory tract infection (38) Neoplasm (36) Abnormality of the cardiovascular system (34) Diabetes mellitus (33) Depressivity (29) Acute kidney injury (27) Hypoxemia (26) Hypertension (24) Abnormal lung morphology (24) Thromboembolism (22) Anosmia (20) Myocardial infarction (20) Arthritis (19) Type II diabetes mellitus (18) Stroke (16) Pulmonary embolism (16) Mental deterioration (15) Abnormality of coagulation (15) Pulmonary fibrosis (15) Chronic pulmonary obstruction (15) Abnormality of the kidney (14) Autistic behavior (14) Rheumatoid arthritis (14) Leukemia (14) Interstitial pneumonitis (14) Pulmonary obstruction (14) Asthma (13) Chronic pain (13) Congestive heart failure (12) Deep venous thrombosis (12) Neoplasm of the lung (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Ulcerative colitis (11) Crohn's disease (11) Type I diabetes mellitus (10) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Chronic kidney disease (9) Myocarditis (9) Behavioral abnormality (8) Psychosis (8) Dementia (8) Alzheimer disease (8) Carcinoma (8) Low levels of vitamin D (8) Sepsis (8) Infertility (7) Peripheral arterial stenosis (7) Renal insufficiency (6) Lymphopenia (6) Dysphagia (6) Lymphoma (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Breast carcinoma (6) Psoriasiform dermatitis (6) Abnormality of the gastrointestinal tract (6) Fatigue (6) Encephalopathy (5) Premature birth (5) Bronchiectasis (5) Difficulty walking (5) Gastroparesis (5) Immunodeficiency (5) Obstructive sleep apnea (5) Autoimmunity (5) Knee osteoarthritis (5) Sleep apnea (5) Prostate cancer (5) Allergy (5) Non-small cell lung carcinoma (5) Schizophrenia (5) Neoplasm of the large intestine (5) Seizure (4) Hepatic fibrosis (4) Cardiac arrest (4) Weight loss (4) Migraine (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Neoplasm of the pancreas (4) Colon cancer (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Inflammatory abnormality of the skin (4) Neoplasm of head and neck (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Obsessive-compulsive behavior (3) Eczema (3) Atopic dermatitis (3) Spastic diplegia (3) Abnormal heart morphology (3) Cardiomyopathy (3) Fever (3) Hypothermia (3) Headache (3) Celiac disease (3) Reduced factor VIII activity (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Abnormal anterior horn cell morphology (3) Amyotrophic lateral sclerosis (3) Cystoid macular edema (3) Arrhythmia (3) Cutaneous melanoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Spasticity (2) Meningitis (2) Abnormal joint morphology (2) Hepatic steatosis (2) Hepatic failure (2) Tachycardia (2) Angina pectoris (2) Pancreatitis (2) Abnormality of blood and blood-forming tissues (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Apnea (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Myelodysplasia (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Postprandial hyperglycemia (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) Cervix cancer (2) Small cell lung carcinoma (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Periodontitis (1) IgA deposition in the glomerulus (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Cerebral hemorrhage (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Dilatation (1) Osteomyelitis (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Intermittent claudication (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Venous insufficiency (1) Chronic lymphatic leukemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0000083: Renal insufficiency

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (5)


    Name (Synonyms) Correlation
    drug2763 PF-06882961 20 mg Wiki 0.41
    drug1305 EHR-based Clinician Jumpstart Wiki 0.41
    drug486 BMS-986259 Wiki 0.41
    Name (Synonyms) Correlation
    drug1118 CytoSorb 300 mL device Wiki 0.41
    drug2413 Mobocertinib Wiki 0.29

    Correlated MeSH Terms (18)


    Name (Synonyms) Correlation
    D051437 Renal Insufficiency, NIH 1.00
    D016491 Peripheral Vascular Diseases NIH 0.24
    D058729 Peripheral Arterial Disease NIH 0.20
    Name (Synonyms) Correlation
    D014652 Vascular Diseases NIH 0.20
    D008103 Liver Cirrhosis, NIH 0.20
    D009362 Neoplasm Metastasis NIH 0.18
    D007676 Kidney Failure, Chronic NIH 0.15
    D051436 Renal Insufficiency, Chronic NIH 0.14
    D006333 Heart Failure NIH 0.12
    D008175 Lung Neoplasms NIH 0.12
    D017563 Lung Diseases, Interstitial NIH 0.11
    D007674 Kidney Diseases NIH 0.11
    D002908 Chronic Disease NIH 0.11
    D029424 Pulmonary Disease, Chronic Obstructive NIH 0.11
    D003924 Diabetes Mellitus, Type 2 NIH 0.10
    D008171 Lung Diseases, NIH 0.08
    D003920 Diabetes Mellitus, NIH 0.07
    D009369 Neoplasms, NIH 0.07

    Correlated HPO Terms (12)


    Name (Synonyms) Correlation
    HP:0001395 Hepatic fibrosis HPO 0.20
    HP:0004950 Peripheral arterial stenosis HPO 0.15
    HP:0012622 Chronic kidney disease HPO 0.14
    Name (Synonyms) Correlation
    HP:0001635 Congestive heart failure HPO 0.12
    HP:0100526 Neoplasm of the lung HPO 0.12
    HP:0006515 Interstitial pneumonitis HPO 0.11
    HP:0000077 Abnormality of the kidney HPO 0.11
    HP:0006510 Chronic pulmonary obstruction HPO 0.11
    HP:0005978 Type II diabetes mellitus HPO 0.10
    HP:0002088 Abnormal lung morphology HPO 0.08
    HP:0000819 Diabetes mellitus HPO 0.07
    HP:0002664 Neoplasm HPO 0.07

    Clinical Trials

    Navigate: Correlations   HPO

    There are 6 clinical trials


    1 A Phase 1 Pharmacokinetic Study of Oral Mobocertinib in Subjects With Severe Renal Impairment and Normal Renal Function

    The purpose of this study is to characterize the single-dose plasma and urine PK of mobocertinib and its active metabolites (AP32960 and AP32914) in participants with severe RI compared to matched-healthy participants with normal renal function.

    NCT04056455
    Conditions
    1. Renal Impairment
    2. Healthy Volunteers
    Interventions
    1. Drug: Mobocertinib
    MeSH:Renal Insufficiency
    HPO:Renal insufficiency

    Primary Outcomes

    Measure: Cmax: Maximum Observed Plasma Concentration for Mobocertinib and its Active Metabolites (AP32960 and AP32914)

    Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose

    Measure: Cmax,u: Maximum Observed Unbound Plasma Concentration for Mobocertinib and its Active Metabolites (AP32960 and AP32914)

    Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose

    Measure: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Mobocertinib and its Active Metabolites (AP32960 and AP32914)

    Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose

    Measure: AUCinf,u: Area Under the Unbound Plasma Concentration-time Curve From Time 0 to Infinity for Mobocertinib and its Active Metabolites (AP32960 and AP32914)

    Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose

    Measure: AUClast: Area Under the Plasma Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration for Mobocertinib and its Active Metabolites (AP32960 and AP32914)

    Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose

    Measure: AUClast,u: Area Under the Unbound Plasma Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration for Mobocertinib and its Active Metabolites (AP32960 and AP32914)

    Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose

    Measure: Combined Molar Unbound Cmax, for Mobocertinib and its Active Metabolites (AP32960 and AP32914)

    Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose

    Measure: Combined Molar Unbound AUClast, for Mobocertinib and its Active Metabolites (AP32960 and AP32914)

    Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose

    Measure: Combined Molar Unbound AUCinf, for Mobocertinib and its Active Metabolites (AP32960 and AP32914)

    Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose

    Measure: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Mobocertinib and its Active Metabolites (AP32960 and AP32914)

    Time: : Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose

    Measure: t1/2z: Terminal Disposition Phase Half-life for Mobocertinib and its Active Metabolites (AP32960 and AP32914)

    Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose

    Measure: ╬╗z: Terminal Disposition Phase Rate Constant for Mobocertinib and its Active Metabolites (AP32960 and AP32914)

    Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose

    Measure: CL/F: Apparent Clearance After Extravascular Administration for Mobocertinib

    Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose

    Measure: CLu/F: Apparent Clearance for Unbound Drug After Extravascular Administration for Mobocertinib

    Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose

    Measure: Vz/F: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration for Mobocertinib

    Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose

    Measure: Vz,u/F: Apparent Volume of Distribution for Unbound Drug During the Terminal Disposition Phase After Extravascular Administration for Mobocertinib

    Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose

    Measure: Aet: Amount of Drug Excreted in Urine From Time 0 to time t for Mobocertinib and its Active Metabolites (AP32960 and AP32914)

    Time: Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose

    Measure: fe,t: Fraction of Administered Dose Excreted in Urine From Time 0 to Time t for Mobocertinib and its Active Metabolites (AP32960 and AP32914)

    Time: Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose

    Measure: CLR: Renal Clearance for Mobocertinib and its Active Metabolites (AP32960 and AP32914)

    Time: Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose

    Secondary Outcomes

    Measure: Plasma Protein Binding of Mobocertinib and its Active Metabolites (AP32960 and AP32914)

    Time: Day 1 at multiple time points (up to 24 hours) post-dose

    Measure: Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs)

    Time: Baseline up to 30 days after the last of study drug (Day 31)
    2 A Phase 1, Open-Label, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986259 in Participants With Varying Degrees of Renal Function

    A study to evaluate the drug effect, safety, and tolerability of BMS-986259 in participants with different levels of kidney function

    NCT04237831
    Conditions
    1. Renal Failure
    Interventions
    1. Drug: BMS-986259
    MeSH:Renal Insufficiency
    HPO:Renal insufficiency

    Primary Outcomes

    Measure: Maximum plasma Concentration (Cmax) of BMS-986259 in Blood serum

    Time: Day 1 and Day 8

    Measure: Time to reach maximum concentration in plasma (Tmax) of BMS-986259 in blood serum

    Time: Day 1 and Day 8

    Measure: Area under the concentration- time curve over the dosing interval of BMS-986259 in blood serum - AUC(TAU)

    Time: Day 1 and Day 8

    Measure: Concentration of BMS-986259 in blood serum at 24 hours (C24)

    Time: Day 1 and Day 8

    Measure: Area under the concentration-time curve of BMS-986259 from time 0 (dosing) to the time of the last quantifiable - AUC(0-T)

    Time: Day 8

    Measure: Accumulation ratio in the maximum plasma concentration of BMS-986259 in blood serum -AR(Cmax)

    Time: Day 8

    Measure: Accumulation ratio of Area under the concentration-time curve in BMS-986259 over the dosing interval -AR (AUC [TAU])

    Time: Day 8

    Measure: Accumulation ratio concentration of BMS-986259 at 24 hours- AR(C24)

    Time: Day 8

    Measure: Terminal elimination half-life of BMS-986259 (T-HALF)

    Time: Day 8

    Measure: Apparent total clearance of BMS-986259 at steady-state (CLss/F)

    Time: Day 8

    Measure: Apparent volume of distribution of BMS-986259 at terminal phase at steady-state (Vss/F)

    Time: Day 8

    Secondary Outcomes

    Measure: Incidence of Non serious Adverse Events (AEs)

    Time: Up to 4 months

    Measure: Incidence of Serious Adverse Events (SAEs)

    Time: Up to 4 months

    Measure: Incidence of AEs leading to discontinuation

    Time: Up to 4 months

    Measure: Number of clinically significant changes in vital signs

    Time: Up to 4 months

    Measure: Number in clinically significant changes in Electrocardiogram (ECG)

    Time: Up to 4 months

    Measure: Number of clinically significant changes in physical examinations

    Time: Up to 4 months

    Measure: Number of clinically significant changes in clinical laboratory tests

    Time: Up to 4 months
    3 Using the Electronic Health Record to Identify and Promote Goals-of-Care Communication for Older Patients With Serious Illness

    The objective of this protocol is to test the effectiveness of a Jumpstart intervention on patient-centered outcomes for patients with chronic illness by ensuring that they receive care that is concordant with their goals over time, and across settings and providers. This study will examine the effect of the EHR-based intervention to improve quality of palliative care for patients over the age of 65 with chronic, life-limiting illness with a particular emphasis on Alzheimer's disease and related dementias (ADRD). The specific aims are: 1) to evaluate the effectiveness of a novel EHR-based (electronic health record) clinician Jumpstart guide, compared with usual care, for improving the quality of care; the primary outcome is documentation of a goals-of-care discussion during the hospitalization. Secondary outcomes focus on intensity of care: ICU use, ICU and hospital length of stay, costs of care during the hospitalization, and 30-day hospital readmissions; and 2) to conduct a mixed-methods evaluation of the implementation of the Jumpstart intervention, guided by the RE-AIM and CFIR frameworks for implementation science, incorporating quantitative assessments of effectiveness, implementation and maintenance and qualitative assessments of clinician perspectives on barriers and facilitators to future implementation and dissemination.

    NCT04281784
    Conditions
    1. Dementia
    2. Chronic Disease
    3. Neoplasm Metastasis
    4. Lung Neoplasm
    5. Pulmonary Disease, Chronic Obstructive
    6. Heart Failure´╝îCongestive
    7. Liver Cirrhosis
    8. Kidney Failure, Chronic
    9. Lung Diseases, Interstitial
    10. Peripheral Vascular Disease
    11. Diabetes With End Organ Injury
    12. Palliative Care, Patient Care
    13. Health Care Quality, Access, and Evaluation
    14. Patient Care
    15. Inpatients
    16. Health Communication
    17. Patient Care Planning
    Interventions
    1. Behavioral: EHR-based Clinician Jumpstart
    MeSH:Neoplasms Neoplasm Metastasis Lung Neoplasms Liver Cirrhosis Lung Diseases Pulmonary Disease, Chronic Obstructive Lung Diseases, Interstitial Renal Insufficiency Kidney Failure, Chronic Heart Failure Vascular Diseases Peripheral Vascular Diseases Peripheral Arterial Disease Chronic Disease
    HPO:Abnormal left ventricular function Abnormal lung morphology Chronic pulmonary obstruction Cirrhosis Congestive heart failure Hepatic fibrosis Interstitial pneumonitis Interstitial pulmonary abnormality Neoplasm Neoplasm of the lung Peripheral arterial stenosis Renal insufficiency Right ventricular failure

    Primary Outcomes

    Description: The primary outcome is the proportion of patients who have a goals-of-care (GOC) discussion that has been documented in the EHR in the period between randomization and 30 days following randomization The proportion is the number of patients with GOC documentation over the number of patients in each study arm. Documentation of goals-of-care discussions will be evaluated using our NLP/ML methods. Study staff will manually review and compare findings using a randomly-selected sample of charts using our standard EHR abstraction methods; manual chart abstraction will be the gold standard.

    Measure: EHR documentation of Goals of Care discussions

    Time: Assessed for the period between randomization and 30 days following randomization

    Secondary Outcomes

    Description: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of ICU admissions during the patient's (index) hospital stay will be collected from the EHR using our automated and validated methods.

    Measure: Intensity of care/ICU use: ICU admissions

    Time: Assessed for the period between randomization and 30 days following randomization

    Description: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of days the patient spent in the ICU during their (index) hospital stay will be collected from the EHR using our automated and validated methods.

    Measure: Intensity of care/ICU use: ICU length of stay

    Time: Assessed for the period between randomization and 30 days following randomization

    Description: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of days the patient spent in the hospital during that (index) hospital stay will be collected from the EHR using our automated and validated methods.

    Measure: Intensity of care/Hospital use: Hospital length of stay

    Time: Assessed for the period between randomization and 30 days following randomization

    Description: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of hospital readmissions between randomization and 30 days following randomization will be collected from the EHR using our automated and validated methods.

    Measure: Intensity of care: Hospital Readmissions 30 days

    Time: Assessed for the period between randomization and 30 days following randomization

    Description: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of ICU readmissions between randomization and 30 days following randomization will be collected from the EHR using our automated and validated methods.

    Measure: Intensity of care: ICU Readmissions 30 days

    Time: Assessed for the period between randomization and 30 days following randomization

    Description: Costs for intervention vs. control will be reported in US dollars and identified from UW Medicine administrative financial databases. Costs will be reported for total hospital costs and disaggregated costs (direct-variable, direct fixed, indirect costs). Direct-variable costs will include supply and drug costs. Direct-fixed costs will include labor, clinical department administration, and overhead fees. Indirect costs represent services provided by cost centers not directly linked to patient care such as information technology and environmental services. Costs for ED (emergency department) days and ICU days will be similarly assessed.

    Measure: Intensity of care: Healthcare costs

    Time: 1 and 3 months after randomization

    Description: From Washington State death certificates.

    Measure: All-cause mortality at 1 year (safety outcome)

    Time: 1 year after randomization

    Other Outcomes

    Description: Qualitative interviews after individual participation. Interviews will be guided by the RE-AIM and Consolidated Framework for Implementation Research (CFIR) to explore the factors associated with implementation (e.g., reach, maintenance, feasibility, inner and outer settings, individuals, and processes of care.) Individual constructs within these domains were chosen to fit this specific intervention and context.

    Measure: Key Implementation Factors

    Time: 3 months after randomization
    4 Antistof Respons Mod SARS-CoV-2 Hos Dialysepatienter i Forbindelse Med COVID-19

    Determination of IgM and IgG antibodies against SARS-CoV-2 in dialysis patients by continous monitoring in the period from March 2020 to december 2020

    NCT04367714
    Conditions
    1. COVID
    2. Terminal Renal Insufficiency
    MeSH:Renal Insufficiency
    HPO:Renal insufficiency

    Primary Outcomes

    Description: IgM and IgG against SARS-CoV-2

    Measure: AAntibody response

    Time: 1 year
    5 Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection

    The coronavirus (COVID-19) pandemic has created a significant strain on health care resources across the world for managing critically ill patients. Emerging reports from China, South Korea and Italy have reported varying incidence of acute kidney (AKI) ranging from 5-15% with a mortality of 60-80% however there is no systematic assessment of the risk factors, recognition, course and outcomes in patients with and without kidney disease whose course is complicated by AKI1-4. Patients with underlying CKD, immunosuppressed patients with renal transplants and ESKD patients are at high risk for COVID-19 infection and there is limited information on the effect of COVID-19 on the course and outcomes of these patients. The requirement for renal support including IHD, CRRT and sorbent based therapies has been variable and has contributed to the intense pressure on the nephrology and critical care providers for delivering these therapies. As the COVID-19 pandemic expands in the USA and abroad, there is an intense need to understand the epidemiology of the disease and the resources needed for renal support to inform clinical management and public health interventions. In this study, the investigators aim to investigate health care facilities across the world (hospital wards, ICU, outpatient clinics, nursing homes, healthcare centers) to draw a global picture of incidence, risk factors, resources available for treatment and prognosis of acute and chronic kidney disease in patient with COVID 19 confirmed infection. The aim is to identify trends in patients with acute and chronic kidney disease, determine its incidence, treatment and outcomes in different settings across the world. This information will be used to develop and implement educational tools and resources to prevent deaths from AKI and progression of CKD in this and following pandemics.

    NCT04491227
    Conditions
    1. Covid19
    2. AKI
    3. CKD
    4. ESRD
    5. Transplant;Failure,Kidney
    MeSH:Kidney Diseases Renal Insufficiency, Chronic Renal Insufficiency
    HPO:Abnormality of the kidney Chronic kidney disease Nephropathy Renal insufficiency

    Primary Outcomes

    Description: Meeting of at least one of the modified KDIGO Criteria Increase or decrease in serum creatinine >0.3 mg/dl from reference in 48 hours Increase or decrease in serum creatinine > 50% from reference in 7 days Urine output < 400 ml/day

    Measure: AKI incidence

    Time: from hospital admission through hospital discharge upto 24 weeks

    Description: initiation of intermittent hemodialysis, continuous hemodialysis or peritoneal dialysis during the hospital stay

    Measure: Dialysis requirement

    Time: through study completion upto 1 year from enrollment

    Description: Deaths during primary hospitalization

    Measure: hospital mortality

    Time: through study completion within 1 year

    Secondary Outcomes

    Description: C-Complete: SCr < 0.3 mg/dL from reference P-Partial: Requires no dialysis but not complete recovery N-No recovery: Dialysis dependent C-Complete: SCr < 0.3 mg/dL from reference P-Partial: Requires no dialysis but not complete recovery N-No recovery: Dialysis dependent Percentage of patinets with renal functioanl recovery based on serum creatinien levels classfied as C-Complete: SCr < 0.3 mg/dL from reference P-Partial: Requires no dialysis but not complete recovery N-No recovery: Dialysis dependent

    Measure: Renal functional recovery

    Time: Assessed at at 3, 6 and 12 months from enrollment at hospital admission

    Description: EQL5D scale and SH8 scales completed at 3, 6 and 12 months post enrollment

    Measure: Functional status

    Time: questionnaires to be completed at 3, 6 and 12 months from enrollment at hospital admission

    Description: Number of days patient is in the hospital and ICU and is managed with ventilators, dialysis or other extracorporeal organ support e.g. ECMO during the hospital stay

    Measure: Resource utilization

    Time: Within 1 year of enrollment for primary hospitalization
    6 OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP STUDY TO EVALUATE THE PHARMACOKINETICS OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT RENAL IMPAIRMENT

    This study will characterize the effect of varying degrees of renal impairment on the pharmacokinetics (PK), safety and tolerability of a single oral dose of PF- 06882961 compared with participants with normal renal function.

    NCT04616027
    Conditions
    1. Diabetes Mellitus, Type 2
    2. Renal Impairment
    3. Healthy
    Interventions
    1. Drug: PF-06882961 20 mg
    MeSH:Renal Insuffici Renal Insufficiency Diabetes Mellitus Diabetes Mellitus, Type 2
    HPO:Diabetes mellitus Renal insufficiency Type II diabetes mellitus

    Primary Outcomes

    Measure: Maximum plasma concentration [C(max)]

    Time: Hour 0, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 16 on Day 1, Hour 24 and 36 on Day 2, Hour 48 on Day 3

    Measure: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC(inf)]

    Time: Hour 0, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 16 on Day 1, Hour 24 and 36 on Day 2, Hour 48 on Day 3

    Measure: Area under the plasma concentration-time [AUC(last)]

    Time: Hour 0, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 16 on Day 1, Hour 24 and 36 on Day 2, Hour 48 on Day 3

    Measure: Fraction of unbound drug in plasma [fu]

    Time: Hour 0, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 16 on Day 1, Hour 24 and 36 on Day 2, Hour 48 on Day 3

    Secondary Outcomes

    Measure: Unbound Maximum Observed Plasma Concentration [C(max,u)]

    Time: Hour 0 and 4 on Day 1

    Measure: Unbound area under the plasma concentration-time profile from time zero extrapolated to infinite time [AUC(inf,u)]

    Time: Hour 0 and 4 on Day 1

    Measure: Unbound area under the plasma concentration time profile from time zero to the time of the last quantifiable concentration [AUC[last,u])

    Time: Hour 0 and 4 on Day 1

    Measure: Apparent Oral Clearance [CL/F]

    Time: Hour 0 and 4 on Day 1

    Measure: Apparent clearance of unbound drug [CL(u)/F]

    Time: Hour 0 and 4 on Day 1

    Measure: Apparent volume of distribution [V(z)/F]

    Time: Hour 0 and 4 on Day 1

    Measure: Time to Reach Maximum Observed Plasma Concentration [T(max)]

    Time: Hour 0 and 4 on Day 1

    Measure: Time measured for plasma concentration to decrease by one half (Terminal half-life) [t(1/2)].

    Time: Hour 0 and 4 on Day 1

    Measure: Incidence and severity of treatment emergent adverse events (AEs and SAEs)

    Time: Baseline through Day 28

    Measure: Incidence of treatment emergent clinical laboratory abnormalities

    Time: Baseline to Day 3

    Measure: Incidence of treatment emergent vital signs

    Time: Baseline, Day 1 and Day 3

    Measure: Incidence of treatment emergent Electrocardiogram [ECG] abnormalities

    Time: Baseline, Day 1 and Day 3

    HPO Nodes


    HP:0000083: Renal insufficiency
    Genes 449
    ALOXE3 WT1 TRNT MMUT COL7A1 CFHR5 FXYD2 LIMK1 GSN ERCC8 LAGE3 BBS10 PGAM2 FAM20A NTRK1 DZIP1L FANCI MLXIPL LEMD3 NOTCH2 SALL1 SEC61A1 AGXT CLCN5 MAPKBP1 DYNC2I1 RYR1 NPHP3 CLDN19 NPHP3 HLA-DPB1 KCTD1 SCNN1A TRAF3IP1 SLX4 HPRT1 ABCA12 PKD1 CDC73 RPGRIP1L WDR19 TTC21B NPHP4 PRPS1 ELN SMARCAL1 OCRL SIX5 GPR35 PKD2 NPHP3 EIF2AK3 TP53RK RAD51 ERCC4 CCR6 NLRP3 LMX1B HPRT1 TGM1 EIF2AK3 GTF2I NPHP1 CACNA1S NSD1 FANCL CTLA4 STS KYNU MDM2 TCF4 WDR19 MAFB TRPC6 LIPN ERCC4 APRT TMEM67 INPP5E WDR73 TMEM67 ERCC4 PBX1 PTPN22 COL4A5 NPHP1 NPHP3 RASGRP1 SIX1 WT1 GLA WDR19 BICC1 COL4A1 SDCCAG8 DHDDS KMT2A FANCE RAD21 HLA-B GATA3 ALMS1 INVS PYGM NEK8 FANCM WT1 FASLG CFHR3 SAA1 MEFV MYCN NPHP1 OSGEP NPHP1 LRIG2 FAM20A FLT1 INVS HBB SLC3A1 SLC22A12 SCARB2 PNPLA6 HLA-DRB1 JAG1 ALOX12B DYNC2LI1 VANGL1 CLCN5 WDR73 CLDN16 NIPBL FANCG RAD51C DNAJB11 DYNC2H1 MYOCD TSC1 FAS CFB OCRL UBAC2 MUC1 MST1 PRDX1 PUS3 CRB2 CYP4F22 HPSE2 HLA-B NPHP4 MMACHC APOE ALMS1 PAX6 AQP2 HDAC8 TRAF3IP1 WT1 TBC1D8B OCLN HELLPAR DCDC2 THBD NPHP4 NPHP1 TMEM231 STAT2 CSPP1 PALB2 SIX5 IRAK1 HNF1B SOX18 LZTFL1 ERAP1 SMC1A NPHS2 SARS2 TMEM231 PRTN3 CD151 ERCC6 PKHD1 CFHR1 BTNL2 HNF1B FN1 FANCB ANKS6 SDCCAG8 SLC7A9 IL12A ERCC8 OCRL TCN2 IRF5 NUP85 NUP107 C3 PKD1 BBIP1 LDHA FUZ IL23R HLA-DPA1 LHX1 CLPB PEX7 CHD4 CFH PAX2 NPHS1 FAN1 KLRC4 CCND1 CEP290 MYCN IL12A-AS1 IFT80 BSND LCAT IFT122 TRNK MME COL4A1 AP2S1 BNC2 HMBS TMEM237 LMX1B GANAB AMMECR1 TMEM138 GATM CTNS STAT4 SETD2 SULT2B1 IFT172 IFT140 SDR9C7 TMEM216 GRHPR CFI RAD51C COQ8B ZNF423 TRNL1 ZNF592 PKDCC ALDOB CLIP2 OFD1 CEP164 IQCB1 SETD5 FANCF DYNC2I2 EHMT1 UMOD KIAA0586 MYH9 BAZ1B AGXT CFH MAGI2 BICC1 MMUT GCDH FANCD2 CD2AP RMND1 HOXA13 STOX1 RFC2 HPS1 GCM2 HNF1B XRCC2 DNASE1L3 IFT172 SPRY2 GLIS2 NDUFAF6 MEN1 SPP1 APOL1 HRAS TMEM67 CPT2 BRIP1 MOCOS TMEM260 NUP160 PRKCD CEP290 DSTYK PKD2 INF2 SLC7A7 AHI1 CC2D2A CPT2 CORIN CD46 FAH CAV1 CEP83 TMEM67 PGK1 IL10 CLDN10 MEFV COG1 XPNPEP3 MYD88 CLCNKA CFH DGKE SCNN1B WDR19 BRCA1 KCNE5 PLCE1 FANCC IKZF1 UBE2T CDC73 LAMB2 TSC2 COL4A4 MEFV ERCC6 CLCNKB CC2D2A SCNN1B AVPR2 TTC21B ELP1 WDR35 CHRM3 INF2 NUP107 ACTN4 HNF4A FAS CDC73 CLCN5 EYA1 SCNN1G GTF2IRD1 GLA CFI FAS LAMB2 APRT LPIN1 REN NUP93 SMC3 NOD2 STAT4 PAX2 CLCN5 CC2D2A FN1 GATA3 IFT43 COL4A3 TMEM237 SALL1 SLC34A1 SLC37A4 APC2 ARHGDIA FANCA CTNS NUP205 MAD2L2 PPOX PKHD1 CEP290 RPGRIP1L TMEM126B ACP5 CPT2 WDR19 RFWD3 DZIP1L TLR4 ERCC8 IFT140 CCN2 SGPL1 RPGRIP1L SLC30A9 BRCA2 COL4A3 UMOD GRHPR AVIL AMMECR1 CHRNA3 TMEM67 C4A CCNQ TBX18 MYO1E ANLN MMP1 SHPK C3 ELN CEP290 WT1 ACSL4 MMUT PHYH LMX1B CEP120 CFI CD46 TBL2 ERCC6 SLC26A1 CCR1 TPRKB PAX2 LRIG2 HPRT1 TTC21B GSN CPT2 NUP133 PGK1 HSD11B2 NIPAL4 IFT27 DACT1 ITGA3 UMOD HLA-DRB1 IQCB1 CASP10 PTPN22 SH2B1 TRNE
    Protein Mutations 2
    L31F Y93H
    SNP 0

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0000083: Renal insufficiency
    Genes 449
    ALOXE3 WT1 TRNT MMUT COL7A1 CFHR5 FXYD2 LIMK1 GSN ERCC8 LAGE3 BBS10 PGAM2 FAM20A NTRK1 DZIP1L FANCI MLXIPL LEMD3 NOTCH2 SALL1 SEC61A1 AGXT CLCN5 MAPKBP1 DYNC2I1 RYR1 NPHP3 CLDN19 NPHP3 HLA-DPB1 KCTD1 SCNN1A TRAF3IP1 SLX4 HPRT1 ABCA12 PKD1 CDC73 RPGRIP1L WDR19 TTC21B NPHP4 PRPS1 ELN SMARCAL1 OCRL SIX5 GPR35 PKD2 NPHP3 EIF2AK3 TP53RK RAD51 ERCC4 CCR6 NLRP3 LMX1B HPRT1 TGM1 EIF2AK3 GTF2I NPHP1 CACNA1S NSD1 FANCL CTLA4 STS KYNU MDM2 TCF4 WDR19 MAFB TRPC6 LIPN ERCC4 APRT TMEM67 INPP5E WDR73 TMEM67 ERCC4 PBX1 PTPN22 COL4A5 NPHP1 NPHP3 RASGRP1 SIX1 WT1 GLA WDR19 BICC1 COL4A1 SDCCAG8 DHDDS KMT2A FANCE RAD21 HLA-B GATA3 ALMS1 INVS PYGM NEK8 FANCM WT1 FASLG CFHR3 SAA1 MEFV MYCN NPHP1 OSGEP NPHP1 LRIG2 FAM20A FLT1 INVS HBB SLC3A1 SLC22A12 SCARB2 PNPLA6 HLA-DRB1 JAG1 ALOX12B DYNC2LI1 VANGL1 CLCN5 WDR73 CLDN16 NIPBL FANCG RAD51C DNAJB11 DYNC2H1 MYOCD TSC1 FAS CFB OCRL UBAC2 MUC1 MST1 PRDX1 PUS3 CRB2 CYP4F22 HPSE2 HLA-B NPHP4 MMACHC APOE ALMS1 PAX6 AQP2 HDAC8 TRAF3IP1 WT1 TBC1D8B OCLN HELLPAR DCDC2 THBD NPHP4 NPHP1 TMEM231 STAT2 CSPP1 PALB2 SIX5 IRAK1 HNF1B SOX18 LZTFL1 ERAP1 SMC1A NPHS2 SARS2 TMEM231 PRTN3 CD151 ERCC6 PKHD1 CFHR1 BTNL2 HNF1B FN1 FANCB ANKS6 SDCCAG8 SLC7A9 IL12A ERCC8 OCRL TCN2 IRF5 NUP85 NUP107 C3 PKD1 BBIP1 LDHA FUZ IL23R HLA-DPA1 LHX1 CLPB PEX7 CHD4 CFH PAX2 NPHS1 FAN1 KLRC4 CCND1 CEP290 MYCN IL12A-AS1 IFT80 BSND LCAT IFT122 TRNK MME COL4A1 AP2S1 BNC2 HMBS TMEM237 LMX1B GANAB AMMECR1 TMEM138 GATM CTNS STAT4 SETD2 SULT2B1 IFT172 IFT140 SDR9C7 TMEM216 GRHPR CFI RAD51C COQ8B ZNF423 TRNL1 ZNF592 PKDCC ALDOB CLIP2 OFD1 CEP164 IQCB1 SETD5 FANCF DYNC2I2 EHMT1 UMOD KIAA0586 MYH9 BAZ1B AGXT CFH MAGI2 BICC1 MMUT GCDH FANCD2 CD2AP RMND1 HOXA13 STOX1 RFC2 HPS1 GCM2 HNF1B XRCC2 DNASE1L3 IFT172 SPRY2 GLIS2 NDUFAF6 MEN1 SPP1 APOL1 HRAS TMEM67 CPT2 BRIP1 MOCOS TMEM260 NUP160 PRKCD CEP290 DSTYK PKD2 INF2 SLC7A7 AHI1 CC2D2A CPT2 CORIN CD46 FAH CAV1 CEP83 TMEM67 PGK1 IL10 CLDN10 MEFV COG1 XPNPEP3 MYD88 CLCNKA CFH DGKE SCNN1B WDR19 BRCA1 KCNE5 PLCE1 FANCC IKZF1 UBE2T CDC73 LAMB2 TSC2 COL4A4 MEFV ERCC6 CLCNKB CC2D2A SCNN1B AVPR2 TTC21B ELP1 WDR35 CHRM3 INF2 NUP107 ACTN4 HNF4A FAS CDC73 CLCN5 EYA1 SCNN1G GTF2IRD1 GLA CFI FAS LAMB2 APRT LPIN1 REN NUP93 SMC3 NOD2 STAT4 PAX2 CLCN5 CC2D2A FN1 GATA3 IFT43 COL4A3 TMEM237 SALL1 SLC34A1 SLC37A4 APC2 ARHGDIA FANCA CTNS NUP205 MAD2L2 PPOX PKHD1 CEP290 RPGRIP1L TMEM126B ACP5 CPT2 WDR19 RFWD3 DZIP1L TLR4 ERCC8 IFT140 CCN2 SGPL1 RPGRIP1L SLC30A9 BRCA2 COL4A3 UMOD GRHPR AVIL AMMECR1 CHRNA3 TMEM67 C4A CCNQ TBX18 MYO1E ANLN MMP1 SHPK C3 ELN CEP290 WT1 ACSL4 MMUT PHYH LMX1B CEP120 CFI CD46 TBL2 ERCC6 SLC26A1 CCR1 TPRKB PAX2 LRIG2 HPRT1 TTC21B GSN CPT2 NUP133 PGK1 HSD11B2 NIPAL4 IFT27 DACT1 ITGA3 UMOD HLA-DRB1 IQCB1 CASP10 PTPN22 SH2B1 TRNE
    Protein Mutations 2
    L31F Y93H
    SNP 0

    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook